Obesity alters the macrophages' response to Leishmania major in C57BL/6 mice.

Martins, Vinicius Dantas; Vaz, Leonardo; Barbosa, Sara Candida; Paixão, Pierre Henrique de Menezes; Torres, Licia; Oliveira, Marcos Felipe Andrade de; Oliveira, Mariana de Almeida; Vieira, Leda Quercia; Faria, Ana Maria Caetano de; Maioli, Tatiani Uceli

Obesity is a global pandemic associated with several comorbidities, such as cardiovascular diseases and type 2 diabetes. It is also a predisposing factor for infectious diseases, increasing mortality rates. Moreover, diet-induced obesity can cause metabolic fluctuations that affect macrophage differentiation in various organs. In this sense, we investigated how bone marrow-derived macrophages and tissue-resident macrophages in the skin, which have been differentiated in a host with metabolic syndrome and with previous inflammatory burden, respond to Leishmania major infection. Our findings suggest that bone marrow-derived macrophages from obese C57BL/6 mice, even when cultivated in vitro with inflammatory stimuli, are more susceptible to L. major. These macrophages produce less tumor necrosing factor (TNF) and nitric oxide (NO) and show higher arginase activity. Furthermore, obese mice infected with an intermediate dose of L. major in the skin had more severe lesions when analyzed for ulceration, diameter, thickness, and parasite burden. The increase in lesion severity in obese mice was associated with a higher frequency of tissue-resident macrophages, which are less efficient in killing parasites. We also used CCR2−/− mice, which predominantly have tissue-resident macrophages, and found that lesion resolution was delayed in association with CCR2 deficiency. Additionally, obesity potentiated tissue damage, resulting in higher frequency of tissue-resident macrophages. Our results demonstrate that obesity can alter macrophage responses to infection, leading to increased susceptibility to L. major and more severe cutaneous leishmaniasis. These findings may have important implications for managing obesity-related infections and the development of new therapies for cutaneous leishmaniasis.

CUTANEOUS leishmaniasis; TYPE 2 diabetes; LEISHMANIA major; METABOLIC syndrome; CARDIOVASCULAR diseases

Journal of Leukocyte Biology, 2024, Vol 116, Issue 6, p1372

0741-5400

Academic Journal

10.1093/jleuko/qiae171